Microsoft, weight reduction drug gross sales, and GSK income surge

In at the moment’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory agency Wedbush Securities – to debate Microsoft’s revenues and AI.

Ian Johnston, international pharmaceutical correspondent on the Financial Times, discusses gross sales of common weight reduction drug ‘Wegvoy’, made by Novo Nordisk – as they are saying their gross sales virtually quadrupled final 12 months.

And, Ian discusses GSK’s working revenue of £8.8bn for 2023 with robust promoting medicines together with its HIV and shingles treatment.